微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2015, Vol. 7 ›› Issue (6): 407-410.doi: 10.3969/j.issn.1674-5671.2015.06.05

• 临床研究 • 上一篇    下一篇

贝伐珠单抗联合多西他赛治疗HER-2阴性复发转移性乳腺癌的临床疗效

  

  1. 郑州大学附属洛阳中心医院肿瘤二病区
  • 出版日期:2015-12-25 发布日期:2016-01-11

Efficacy of bevacizumab combined with docetaxel to treat Her-2-negative metastatic breast cancer

  • Online:2015-12-25 Published:2016-01-11

PDF (PC)

480

赞

被引次数

7

摘要：

目的 观察贝伐珠单抗联合多西他赛治疗人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）阴性复发转移性乳腺癌的临床疗效。方法  79例HER-2阴性复发转移性乳腺癌患者根据不同化疗方案分为两组，观察组42例给予贝伐珠单抗联合多西他赛治疗，对照组37例给予多西他赛单药治疗，观察两组患者治疗后的临床疗效和1年、2年生存率及生存期。 结果 观察组总有效率为59.52%，对照组为37.84%，两组比较差异无统计学意义（P＞0.05）；观察组患者部分缓解率为47.62%，显著高于对照组的24.32%（P＜0.05）；观察组患者2年生存率为40.28%，高于对照组的16.22%（P＜0.05）；观察组患者贫血、血小板减少的发生率显著高于对照组（P＜0.05）。 结论 贝伐珠单抗联合多西他赛治疗HER-2阴性复发转移性乳腺癌的疗效较好，可提高患者生存率和生存期，但对患者血液系统影响较为明显，值得临床重视。

关键词: 乳腺肿瘤, 贝伐珠单抗, 多西他赛, 复发转移性乳腺癌, 人表皮生长因子受体-2

Abstract:

Objective To investigate the efficacy of bevacizumab in combination with docetaxel to treat Her-2-negative metastatic breast cancer. Methods  Patients received either bevacizumab in combination with docetaxel（n＝42） or docetaxel（n=37）. Curative outcomes were assessed after 4 cycles of therapy during follow-up lasting 3-24 months. Results The total efficacy rate was 59.52% in the group receiving bevacizumab and docetaxel and 37.84% in the group receiving docetaxel，which was a significant difference（P>0.05）. The positive response rate was significantly higher in the group receiving bevacizumab and docetaxel （26.19 vs 24.32%，P<0.05），as was the 2-year survival rate（40.28 vs 16.22%，P<0.05）. At the same time，incidence of anemia and thrombocytopenia was significantly higher in the group receiving bevacizumab and docetaxel. Conclusion Bevacizumab combined with docetaxel can show high efficacy against Her-2-negative metastatic breast cancer，as well as improve the survival rate and survival time. Future studies need to examine ways to reduce the adverse effects of the therapy on blood components.

Key words: Breast neoplasm, Bevacizumab, Docetaxel, Recurrent metastatic breast cancer, HER-2